CliffBio
small molecule

AVYCAZ

AVIBACTAM SODIUM; CEFTAZIDIME

Loss of exclusivityJune 2032latest FDA-listed patent expiry
CompanyAbbVie Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand nameAVYCAZ
Active ingredientAVIBACTAM SODIUM; CEFTAZIDIME
StrengthEQ 0.5GM BASE;2GM/VIAL
Dosage formPOWDER
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalFebruary 2015
Marketing statusRX

Listed patents

PatentExpiresType
8969566June 2032substance
9284314June 2032substance
9695122June 2032substance
8471025August 2031substance
8835455October 2030product
7612087November 2026product
7112592January 2026substance, product

Regulatory exclusivity

CodeExpires
NPPJanuary 2027

More from AbbVie Inc.

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

AVYCAZ patent cliff — loss of exclusivity June 2032 | CliffBio